



The Health theme

3rd call – opportunities & conditions





Contenuti

- **Il Tema Salute nel VII PQ**
- **Informazioni sui risultati dei primi 2 bandi**
- **Novità sul terzo bando**
- **Gli strumenti a nostra disposizione per capire meglio il Work Programme**
- **Aspetti Etici / dossier APRE/ raccomandazioni**



EUROPEAN
COMMISSION

Community research

Main points

- **the 7th Framework programme and the Health THEME (FP7)**
 - **Rationale and approach**
 - **Basic principles**
 - **Outcome of first 2 calls**
 - **News on the 3^o call**
 - **Structure and content**
 - **Factors for success**



EUROPEAN
COMMISSION

Community research

Collaborative research in the Health theme

Main policy drivers:

- **Improving health** of European citizens
- **Increasing competitiveness** of European health-related industries and businesses
- **Addressing global health issues,** including emerging epidemics

Budget:

- **€6.1 billion over 7 years** (2007-2013)



EUROPEAN
COMMISSION

Community research

Scientific excellence at European level

From policy to funding the best research projects:

- The policy for Health research is described in the FP7 specific programme (available on CORDIS)
- Each year, a work programme is prepared by the EC, with the Advisory Group and in consultation with the Programme Committee
- Through calls for proposals the EC invites researchers from all Europe and beyond to submit their proposals
- The very best projects are selected on the basis of evaluation by independent experts (peer review)



Collaborative research

across borders and other barriers

- **between countries:**

- multinational consortia, with at least 3 partners from 27 EU Member States (**MS**) + Associated Countries (**AC**)

eg: Albania, Croatia, FYROM, Iceland, Israel, Liechtenstein, Montenegro, Norway, Serbia, Switzerland, Turkey.

- researchers from **any country in the world** can participate, from industrialised countries and from developing countries.

eg: Argentina, Australia, Brazil, Canada, China, India, Japan, Korea, New-Zealand, Russia, South-Africa, USA,

- **between different types of organizations**

Public & private sector: universities, research centres, large companies, Small and medium-sized enterprises (SMEs), etc.

- **between disciplines:** multidisciplinary, translational research





Submission & evaluation

Basic principles:

- **annual calls – single-stage or two-stage**
- **eligibility check** (partners, limits, scope, deadline)
- **evaluation by panels of independent experts** overseen by Independent Observers
- **3 criteria:**
 - Science & Technology excellence
 - Implementation & Management
 - Potential Impact
- **feedback:** Evaluation Summary Reports (ESRs)

Thresholds:

3/5

3/5

3/5

overall

10/15



Key figures from 1st & 2nd calls

- call: 2007-A (19 April 2007)
 - **budget: € 635 million** (2007)
 - proposals received: 914
 - proposals evaluated: 893 (ineligible 21)
 - **proposals to be funded: 152** (+1)
% of proposals evaluated: 17%
 - av. grant per participant: €412,000

call 2007-B (18 Sept. 2007)

€ 567 million (2008)

902

865 (37)

167

19%

€334,000

➤ SMEs in 120/152 projects (79%)

128/167 (77%)

➤ 299 SMEs involved (19%)

353 (20%)



Key figures from 1st 2 calls in FP7 Health theme

1st call

call: 2007-A (19 April 2007)

- **budget: € 635 million** (2007)
- proposals received: 914
- proposals evaluated: 893
- **ineligible:** 21
 - ceilings not respected: 11
 - minimum n° partners: 5
 - withdrawn, test or incomplete: 5

2nd call

call 2007-B (18 Sept. 2007)

- € 567 million** (2008)
- 902
- 865
- 37
 - 23
 - 11
 - 1
 - out of scope: 3



EUROPEAN
COMMISSION

Community research

Health theme in FP7

1st call, €635m, 152 proposals

pillar 1:

**Biotechnology,
generic tools
& technologies
for health**

23 proposals:

€143m

pillar 2:

**Translating
research for
human health**

109 proposals:

€472m

pillar 3:

**Optimising
the delivery
of health care**

closed


Activity (pillar) 4: **Other actions across the theme**

20 proposals: **€20m**



Health theme in FP7

2nd call, €567m: 167 proposals





the Health theme structure and content of 3rd call

pillar 1:

**Biotechnology,
generic tools
& technologies
for health**

pillar 2:

**Translating
research for
human health**

pillar 3:

**Optimising
the delivery
of health care**

cross-cutting issues: **child health, the health of ageing population
gender-related health issues**

Activity (pillar) 4: **Other actions across the theme**




Selection rates and reserve lists

Outcome of evaluation/selection of 1st & 2nd calls


- above all thresholds: 48-50% of proposals
- short-listed for grant negotiation: 17-19%
i.e. 36-38% of proposals above threshold
- Cut-off for funding:
 - 1st call: 0 proposals funded under 11.0 (only 10 under 12.0)
 - 2nd call: 0 proposals funded under 12.0 (only 2 at 12.0)
- Reserve lists:
 - 1st call: only 1 proposal retrieved
 - 2nd call: not considered yet (5 proposals on reserve lists)

- ✓ Scadenze bandi:
 - ✓ 1° 22 aprile 2007
 - ✓ 2° 18 settembre 2007
- ✓ Budget: 1,2 Miliardi di Euro
- ✓ Proposte ricevute 1816 (gruppi partecipanti: 17.000)
(53% con partecipante italiano; 17% con coordinamento italiano)
- ✓ Ammesse alla negoziazione: 320 [17%] (3209 partecipanti / 275 italiani)
- ✓ Coordinamento italiano: 34 (11%)
- ✓ (Fonte – MiUR)


Nr. Coordinamenti richiesti per paese




Nr. Coordinatori in negoziazione



Coordinatori Italiani



Ripartizione percentuale del "rientro" finanziario sul Budget





New for 3rd call

- Two-stage submission/evaluation for some areas
 - Ceilings introduced for CA & SA

 - specified number of proposals to be funded per topic
 - for most funding schemes (CP-IP, NoE, CA, SA)*
 - “only up to one proposal can be funded” = (max. 1 project)
 - for Small and medium-sized focused research projects (CP-FP)*
 - “one or more proposals can be funded” = (1 or more projects)
- * unless otherwise stated – see work programme, section III, table 4.



Funding schemes in the Health theme (3rd call)

Funding schemes	upper limits	min. partners
Large-scale integrating project (CP-IP)*	€12m	≥3
Network of Excellence (NoE)	€12m	≥3
Small- or medium-scale focussed research project (CP-FP)	€3m or €6m	≥3
Coordination action (CA)**	€1.5m	≥3
Support action (SA)**	€0.5m	≥1

* for CP-IPs there is also a lower limit to the requested EC grant: €6m.

** for CAs and SAs there are some exceptions to the upper limit.

Warning: the limits for minimum and maximum requested EC grant and for the minimum number of partners are **eligibility criteria** !





3rd call for proposals for the Health theme

The 3rd call is expected to be published end-July 2008
(*NEW: 3^o of september*)

- drawing on the budget for 2009: ~€ 593m*
- there will in fact be two calls, published in parallel:
 - **'FP7-HEALTH-2009-single-stage'** **€476 m**
for most areas of the work programme
expected deadline: Nov. 2008 (*december*)
 - **'FP7-HEALTH-2009-two-stage'** **€115 m**
only for areas 1.1 & 2.1.
expected deadlines: Oct. 2008 for 1st stage
Feb. 2009 for 2nd stage

(including €2m for a topic via the ERA-NET call 2009)*

Based on proposals of European Commission services,
subject to confirmation in call text (July 2008).





Introducing two-stage submission/evaluation

- only for areas 1.1 & 2.1
1.1 – High-throughput research and 2.1 – Integrating biological data and processes (large-scale data-gathering and systems biology)
- all 7 topics are for large-scale integrating projects
- one or more proposals can be funded per topic, provided they are of sufficient quality and depending on the budget



Conditions for two-stage submission/evaluation

➤ **First stage:**

- proposal size limited to 8 pages
(5 pages max. on proposed research and expected impact
+ 3 pages max. to describe consortium & financial resources)
- only the coordinator needs to complete the 'A forms'
- Evaluation of **2 criteria** only (S/T quality and Impact)
- **Higher thresholds (tbc)**

➤ **Second stage:**

- only coordinators of proposals passing Stage 1 will be invited to submit full proposals for Stage 2
- evaluation on all **3 criteria**, independently from Stage 1.



Policy priorities: SME participation & Int. Cooperation

Renewed emphasis and measures for:

- **Small and medium-sized enterprises (SMEs)**
 - Participation encouraged in all areas
 - Special topics for SMEs
 - Support actions
 - *more favourable conditions*
- **International Cooperation**
 - Participation possible in all areas
 - Special International Cooperation Actions (SICA)
 - Coordination or Support actions
 - Coordinated programmes and topics



SME participation

More attractive, better adapted conditions

- Medium/long term vision: 7-year programme
- Policy target: 15% of budget = **>€900m in Health**
- Improved conditions in FP7
 - Strong support: up to 75% of total R&D costs and up to 100% for management & training
 - Better protection: IPR rules adapted to SMEs needs
 - Administrative simplification: reduced need for financial checks and bank guarantees



International participation in FP7 – Health theme

Four approaches:

- **All areas are open for international collaboration**
for the so-called 'Third countries' (not MS or AC)
- **Specific International Cooperation Actions**
with partners from 2 MS or AC + 2 from 'Third countries' (2+2)
eg: in 'Neglected diseases' and 'Public health'
- **Coordinated topics with certain countries**
eg: with Russia
- **Programme level cooperation**
i.e. common planning by the EC and the other funding agencies,
leading to projects working towards a common goal,
eg: International Mouse Knockout Consortium





EUROPEAN
COMMISSION

Community research

Topics proposed for 3rd call

All topics and funding schemes are subject to changes pending the outcome of the European Commission's internal consultations and the consultation of the Member States.

To be confirmed in call text published in July 2008 (SEPTEMBER)

For more information: <http://cordis.europa.eu/fp7/health/>



EUROPEAN
COMMISSION

Community research

Scope of research in the Health Theme

- In the Health theme, the Framework programme can support both basic and applied research
- This includes discovery activities, translational research and early clinical trials (normally only phase I and II).



EUROPEAN
COMMISSION

Community research

Collaborative research in the Health theme

1: Biotechnology, generic tools and technologies

- High-throughput research
- Detection, diagnosis and monitoring
- Predicting suitability, safety and efficacy of therapies
- Innovative therapeutic approaches and interventions



1.1 High-throughput research

Topics proposed for 3rd call: via 2-stage submission/evaluation

- **Computational tools for genome annotation and genotype/phenotype data integration.**

Funding scheme: Large-scale integrating project(s), max. € 12m.

- **High throughput tools and technologies to analyse samples in large-scale human biobanks.**

Funding scheme: CP-IP(s), max. € 12m.

- **Tools, technologies and resources for the characterisation of protein functions.**

Funding scheme: CP-IP(s), max. € 12m.

For these topics, which are all for large-scale integrating projects, **more than one project may be funded per topic**, provided they are of sufficient quality and depending on the EC budget available.



1.2 Detection, diagnosis and monitoring

Topics proposed for 3rd call:

- **Development of tools for sensitive and specific detection of proteins and their interactions for diagnostic purposes.**

Funding scheme: CP-FP, max. € 6m. (1 or more projects)

- **Design of methods suited to identify epigenetic factors and their use in the genetic diagnosis of relevant disorders.**

Funding scheme: CP-FP, max. € 3m (1 or more projects)

- **Novel MR-compatible PET detectors for simultaneous PET/MRI imaging.**

Funding scheme: CP-IP, max. € 12m. (max. 1 project)



1.2 Detection, diagnosis and monitoring

Topics proposed for 3rd call:

- **Novel imaging systems for in vivo monitoring and quality control during tumour ion beam therapy.**

Funding scheme: CP-FP, max. € 6m. (max. 1 project)

- **Activatable or *smart in vivo* imaging agents reporting on physico-chemical or molecular changes relevant to the diagnosis and/or monitoring of diseases.**

Funding scheme: CP-FP, max. € 6m. (1 or more projects)

- **Evaluation of the potential health impact of diagnostic imaging agents doses** (...with a focus on either radioactive or non-radioactive imaging agents).

Funding scheme: Support Action, max. € 0.5m. (max. 1 project for each area)



EUROPEAN
COMMISSION

Community research

1.3 Predicting suitability, safety and efficacy of therapies

- *Mainly implemented through IMI*
 - *the Innovative Medicines Initiative*

call published 30 April 2008

for more information: www.imi.europa.eu

- *one exception: 'Alternative testing strategies'*



EUROPEAN
COMMISSION

Community research

1.3 Predicting suitability, safety and efficacy of therapies

Alternative testing strategies

Topic proposed for 3rd call:

- **New initiatives towards the implementation of the Replace, Reduce and Refine strategy.**

Funding scheme: Coordination Action, max. € 1m. (max. 1 project)



1.4 Innovative therapeutic approaches and interventions

Topics proposed for 3rd call:

Regenerative medicine

- **Cell therapy for tissue and organs.**

Funding scheme: CP-IP(s), max. € 12m.

- **Regeneration of tissue using bio-compatible materials & cells.**

Funding scheme: CP-IP(s), max. € 12m.

- **Activation of endogenous cells as an approach to regenerative medicine.**

Funding scheme: CP-IP(s), max. € 12m.

For these topics, which are all for large-scale integrating projects, **more than one project may be funded per topic**, provided they are of sufficient quality and depending on the EC budget available.



EUROPEAN
COMMISSION

Community research

Collaborative research on the Health theme

2: Translating research for human health

- Integrating biological data and processes:
large-scale data gathering, systems biology
- Research on the brain and related diseases,
human development and ageing
- Translational research in major infectious diseases
- Translational research in other major diseases



Integrating biological data...

2.1.1 large-scale data gathering

Topics proposed for 3rd call: via 2-stage submission/evaluation

- **Large-scale functional genomics effort in multi-cellular organisms to elucidate the function of human genes products.**

Funding scheme: CP-IP(s), max. € 12m.

- **Large-scale functional genomics efforts to identify molecular determinants of cancer.**

Funding scheme: CP-IP(s), max. € 12m.

- **Characterisation of human genetic variation in Europe.**

Funding scheme: CP-IP(s), max. € 12m.

For these topics, which are all for large-scale integrating projects, **more than one project may be funded per topic**, provided they are of sufficient quality and depending on the EC budget available.



EUROPEAN
COMMISSION

Community research

2.1.2 – Systems biology

Topic proposed for 3rd call: via 2-stage submission/evaluation

- **Systems biology approaches for basic biological processes relevant to health and disease.**

Funding scheme: CP-IP(s), max. € 12m.

For this topic, which is for large-scale integrating projects, **more than one project may be funded**, provided they are of sufficient quality and depending on the EC budget available.



2.2.1 – Research on the Brain and related diseases

Topics proposed for 3rd call:

- **Synaptopathies: genesis, mechanisms and therapy.**

Funding scheme: CP-IP, max. € 12m. (max. 1 project)

- **Identifying genetic and environmental interactions in schizophrenia.**

Funding scheme: CP-IP max. € 12m. (max. 1 project)

- **Optimising current therapeutic approaches to schizophrenia.**

Funding scheme: CP-IP, max. € 12m (max. 1 project)

- **Understanding the blood brain barrier (BBB) to improve drug delivery to the brain.**

Funding scheme: CP-FP, max. € 3m. (1 or more projects)

- **Psycho-social factors of brain disorders.**

Funding scheme: Coordination Action, max. € 1.5m. (max. 1 project)



EUROPEAN
COMMISSION

Community research

2.2.2 – Human development and ageing

Temporary closure of this area

No topics in this call



2.3.1 – Anti-microbial drug resistance

Topics proposed for 3rd call:

- **Global collaborative research on the prevention of antibiotic resistance.** Funding scheme: CP-IP, max. € 12m. (max. 1 project)
- **Impact of specific antibiotic therapies on the prevalence of resistant bacteria in the human host.**
Funding scheme: CP-FP, max. € 6m. (1 or more projects)
- **Clinical evaluation of point-of-care diagnostic tests for microbial detection and identification, antibiotic susceptibility determination and biomarkers.**
Funding scheme: CP-FP, max. € 6m. (1 or more projects)



2.3.2 – HIV/AIDS, malaria & TB

Topics proposed for 3rd call:

- **Integration of European efforts in research on malaria.**

Funding scheme: Network of Excellence, max. € 12m. (max. 1 project)

- **Identification and pre-clinical testing of new vaccine candidates for tuberculosis.**

Funding scheme: CP-IP, max. € 12m. (max. 1 project)

- **Discovery and/or development of new and promising anti-HIV microbicides.**

Funding scheme: CP-IP, max. € 12m. (max. 1 project)

- **Mucosal and topical vaccines for poverty related diseases (HIV/AIDS, malaria and/or TB).**

Funding scheme: CP-IP, max. € 12m. (max. 1 project)



2.3.2 – HIV/AIDS, malaria & TB

Topic proposed for 3rd call:

- **Translational vaccine research for poverty-related diseases (HIV/AIDS, malaria and/or TB).**

Funding scheme: CP-FP, max. € 3m. (max. 1 project)

Topic to be implemented through ERA-NET joint call*

- **ERA-NET for stepping up European co-operation in HIV/AIDS research.**

Funding scheme: ERA-Net Coordination Action, max. € 2m. (max. 1 project)

* with a distinct deadline



EUROPEAN
COMMISSION

Community research

2.3.3 – Potentially new and re-merging epidemics

Topic proposed for 3rd call:

- **Efficacy and effectiveness of personal protection equipment and other measures against influenza transmission.**

Funding scheme: CP-FP, max. € 3m. (max. 1 project)



2.3.4 Neglected infectious diseases

Topics proposed for 3rd call: **published under area 4.3.1**

- **Discovery and development of new vaccines or drugs for helminth infections (SICA).** Target region: ICPC.
Funding scheme: CP-FP max. € 6m. (1 or more projects)
- **Identification and development of vaccine candidates for neglected bacterial infections (SICA).** Target region: ICPC.
Funding scheme: CP-FP max. € 6m. (1 or more projects)
- **Human Immune Responses to co-infections of Poverty-Related (HIV, malaria, TB) and Neglected Infectious Diseases (SICA).** Target region: ACP.
Funding scheme: CP-IP, max. € 12m. (max 1 project)

ICPC: International Cooperation Partner Countries

ACP: African, Caribbean and Pacific countries



EUROPEAN
COMMISSION

Community research

2.4.1 – Cancer

Temporary closure of this area

No topics in this call.



2.4.2 – Cardiovascular disease

Topics proposed for 3rd call:

- **Improved or new therapeutic approaches for the treatment of heart failure.** Funding scheme: CP-IP, max. € 12m. (max 1 project)
- **Cardiac arrhythmias: from genes to improved management of patients.** Funding scheme: CP-IP, max. € 12m. (max 1 project)
- **Translation of basic knowledge on inherited cardiomyopathies into clinical practice.**
Funding scheme: CP-FP, max. € 3m. (1 or more projects)



2.4.3 – Diabetes and obesity

Topics proposed for 3rd call:

- **Novel therapeutical approach to pregnancy-induced diabetes.**
Funding scheme: CP-FP, max. € 3m. (max. 1 project)
- **Novel immunotherapies for type 1 diabetes.**
Funding scheme: CP-IP, max. € 12m. (max. 1 project)
- **Molecular pathways in food intake at CNS-liver-gut regulation level.** Funding scheme: CP-FP, max. € 3m. (max. 1 project)



2.4.4 – Rare Diseases

Topics proposed for 3rd call:

- **Rare neurological diseases.**

Funding scheme: CP-FP, max. € 6m. (1 or more projects)

- **Preclinical development of substances with a clear potential as orphan drugs.**

Funding scheme: CP-FP, max. € 3m. (1 or more projects)



2.4.5 – Other chronic diseases

Topics proposed for 3rd call:

- **Prevention and treatment of non-alcoholic fatty liver disease (NAFLD).**
Funding scheme: CP-FP, max. €6m. (1 or more projects)
- **Cellular and molecular mechanisms of development of chronic kidney disease (CKD).**
Funding scheme: CP-IP, max. € 12m. (max. 1 project)



EUROPEAN
COMMISSION

Community research

Cooperation programme

Health theme

3: Optimising the delivery of healthcare

- Translating clinical research into clinical practice
- Quality, efficiency and solidarity of healthcare systems
- Enhanced health promotion and disease prevention



3.1 Translating clinical research into practice

Topics proposed for 3rd call:

- **Patient Safety: Effective implementation of prevention strategies for healthcare associated infections.**
Funding scheme: CP-FP, max. € 3m. (1 or more projects)
- **Improve quality and safety of hospital care.**
Funding scheme: CP-FP, max. € 3m. (1 or more projects)
- **Complementary and alternative Medicine.**
Funding scheme: Coordination Action, max. € 1.5m. (max. 1 project)
- **Improved treatment of chronic diseases in developing countries.** Funding scheme: CP-FP, max. € 3m. (1 or more projects)



3.2 Healthcare systems

Topics proposed for 3rd call:

- **Organisation of dementia care.**

Funding scheme: CP-FP, max. € 3m. (1 or more projects)

- **Health care outcomes and cost-benefits.**

Funding scheme: CP-FP, max. € 3m. (1 or more projects)

- **Primary care quality linkage to costs.**

Funding scheme: CP-FP, max. € 3m. (1 or more projects)

- **Impact of cross border collaboration on health services.**

Funding scheme: CP-FP, max. € 6m. (1 or more projects)



3.2 Healthcare systems

Topics proposed for 3rd call:

- **Research access to comparable health care data.**

Funding scheme: Coordination Action, max. € 1.5m. (max. 1 project)

- **Scoping study to address the methodological challenges of quantifying the socio-economic burden of brain diseases compared to other major diseases.**

Funding scheme: Support Action, max. € 0.5m. (max. 1 project)



3.3 Health promotion and disease prevention

Topics proposed for 3rd call:

- **Child and adolescent mental health.**

Funding scheme: CP-FP, max. € 3m. (1 or more projects)

- **Environmental prevention of substance abuse by adolescents**

Funding scheme: CP-FP, max. € 3m. (1 or more projects)

- **Ageing cohorts.**

Funding scheme: CP-IP, max. € 12m. (max. 1 project)

- **Birth/Mother-Child Cohorts co-ordination.**

Funding scheme: Coordination Action, max. € 1.5m. (max. 1 project)

- **European child health research platform.**

Funding scheme: Coordination Action, max. € 1.5m. (max. 1 project)



International Public Health and Health Systems

Topics proposed for 3rd call: **published under area 4.3.2**

- **Strategies and interventions for improving reproductive health (SICA).** Target region: ICPC.
Funding scheme: CP-FP, max. € 3m. (1 or more projects)
- **Access to medicines (SICA).** Target region: ICPC.
Funding scheme: CP-FP, max. € 3m. (1 or more projects)
- **Integration of disease surveillance and health systems response (SICA).** Target region: ACP or Asian countries.
Funding scheme: CP-FP, max. € 3m. (1 or more projects)

ICPC: International Cooperation Partner Countries

ACP: African, Caribbean and Pacific countries



EUROPEAN
COMMISSION

Community research

Collaborative research on the Health theme

4. Actions across the Theme

- **Coordination & Support Actions across the theme**
- **Responding to EU policy needs**
- **Specific International Cooperation Actions (SICAs)**



4.1 Coordination and support actions across the theme

Topics proposed for 3rd call:

- **Monitoring tool and technology transfer analysis for Health theme grants during FP7.**

Funding scheme: Support Action, max. € 1m. (max. 1 project)

- **Dissemination of results from research in Life Sciences and Biotechnology for Health to the general public and/or information multipliers.**

Funding scheme: Coordination or Support Action, max. € 1m (1 or more projects)

- **Targeting publication bias.**

Funding scheme: Support Action, max. € 0.5m. (max. 1 project)



4.2 Responding to EU policy needs

Topics proposed for 3rd call:

- **Adapting off-patent medicines to the specific needs of paediatric populations.**

Funding scheme: CP-FP, max. € 6m. (1 or more projects)

- **Study of the Arrhythmogenic potential of different classes of medicines.**

Funding scheme: CP-FP, max. € 3m. (1 or more projects)

- **Human Papillomavirus Vaccination (HPV) and cervical cancer screening programmes: estimate of impact of different policy options by way of disease modelling and health economics.**

Funding scheme: CP-FP, max. € 3m. (max. 1 project)



4.3 SICAs

Specific International Cooperation Actions

4.3.1 – Neglected infectious diseases

(described under 2.3.4 Neglected infectious diseases)

4.3.2 – International public health and health systems

(described under International Public Health & Health Systems)

4.3.3 – Coordinated topics with Russia



4.3.3 Coordinated topics with Russia

Topics proposed for 3rd call:

- **Comparative population genetic studies on multifactorial diseases (SICA).** Target region: Russia.
Funding scheme: CP-FP, max. € 3m. (max. 1 project)
- **Mechanisms of diabetic and weight-related co-morbidity in heart failure (SICA).** Target region: Russia.
Funding scheme: CP-FP, max. € 3m. (max. 1 project)



EUROPEAN
COMMISSION

Community research

Eligibility issues

Requirements for eligibility:

- be in scope with the work programme
- have the minimum number of eligible partners
- respect limits for min. & max. requested EC contribution
- follow any other specific requirements
- meet the deadline with a complete proposal

=> specified in work programme, chapter III.



Key factors for success in applying for FP7 funding

**Competition is tough:
only the best projects get funded**

- **the proposal must be in scope with the topic and the work programme** (not wishful thinking)
- **the consortium of partners must be excellent and appropriate for the task** (select the right partners)
- **the proposal must address all 3 criteria,**
- **convince the evaluators** (don't rely on reputation),
- **and, of course, respect the basic rules.**
(deadlines, n° participants, ceilings, length, ethics, ...)



EUROPEAN
COMMISSION

Community research

LETTURA INTELLIGENTE del Work Programme?

...richiede del tempo!



EUROPEAN
COMMISSION

Community research

...E gli strumenti adatti **Quali?**



Gli strumenti a nostra disposizione per capire il WP:

1. Reflection Paper (draft 1 febbraio 2008)

- Description and Justification (eventi, conferenze, progetti ecc)
- Progetti finanziati nel primo bando
- Esempio area cancro, pg 27



Poi...

2. Passare alla versione di **Work Programme in draft** (versione marzo, versione aprile)

- APRE ha comparato le 2 versioni evidenziando le parole nuove (aggiunte, eliminate).

PS. Entrambi i docs sono nella intranet APRE




2 versioni a confronto

AREA/ TOPIC	Modifiche evidenziate all'NCP meeting dell 10/11 Aprile	DRAFT <i>WORK PROGRAMME 2009 (DRAFT 10 MARCH 2008 - BIS)</i>
1.1	ok	BIS
1.2	1.2.1 Development of tools for sensitive and specific detection of proteins and their interaction for diagnostic purposes	1.2.1 Development of tools for sensitive and specific detection of proteins and their interaction for diagnostic, prognostic and monitoring purposes



Poi...Focalizzare





EUROPEAN
COMMISSION

Community research

Comprendere a fondo il topic:

Se il contenuto non è ancora chiaro,
(dubbio di carattere scientifico)

...Consultate il National Contact Point
che potrà segnalarvi il funzionario responsabile
per quel topic!

Rivolgetegli domande specifiche!



Quality issues

Quality is a prerequisite for success:

➤ **font size and page number limitations**

- excess pages will not be considered in the evaluation
- not respecting these will affect perceived quality of proposal

➤ **requirements for information on ethics issues***

- insufficient attention to ethics requirements can lead to delays in negotiation or possibly exclusion of proposals.
- not respecting these will affect perceived quality of proposal

* see Guide for Applicants, Annex 4, section 4.



Ethics in the Health theme

Key issues

- for humans: *Informed Consent / Data Protection / Privacy*
- for animals: the 3Rs (Reduce, Replace, Refine)
- for human embryonic stem cells: some restrictions & conditions

3 areas are excluded from funding

- Human reproductive cloning
- Intentional germ line modification
(except research relating to cancer of the gonads which can be funded)
- Creation of human embryos for research or stem cell procurement
(including by means of somatic cell nuclear transfer)

NB: all ethics issues must be recognised and addressed in the proposal.

- Guide for Applicants, Annex 4, section 4.
- Checklist: http://cordis.europa.eu/fp7/ethics_en.html





EUROPEAN
COMMISSION

Community research

Documenti APRE: gli aspetti etici nel VII PQ

A P R E
A G E N Z I A
P E R L A
P R O M O Z I O N E
D E L L A
R I C E R C A
E U R O P E A

Gli aspetti etici nel VII Programma Quadro

Estratto dall'intervista con Mary Fitzgerald, Unità L3, Governance e Etica, a cura di Marta Cahill, Target Innovation, National Contact Point per l'Irlanda.

Le questioni etiche sono diventate di primaria importanza per l'integrità scientifica tanto da essere diventate una pietra angolare del 7 Programma Quadro di Ricerca Scientifica & Tecnologica appena cominciato.

Le proposte inoltrate alla Commissione, infatti, saranno oggetto di un attento esame delle questioni etiche ad esse inerenti da parte di un "Commission's Ethics Review Team": questo anche al fine di dare risposta alle crescenti preoccupazioni del cittadino europeo circa alcune attività di ricerca.

Ciò significa che i consorzi che sottopongono una proposta devono identificarne le questioni etiche e offrire adeguate soluzioni. Le proposte che non affronteranno tali questioni saranno respinte immediatamente, senza alcuna richiesta di chiarimenti da parte della Commissione. Solo nel caso in cui nella proposta le questioni etiche siano affrontate, anche se in maniera non del tutto soddisfacente, sarà possibile fornire chiarimenti e ripresentare la proposta migliorata su tali aspetti. Tali integrazioni comportano, in ogni caso, un ritardo nella stipula del contratto. Il messaggio è quindi: siate esaurienti e precisi da subito!



EUROPEAN
COMMISSION

Community research




http://cordis.europa.eu/fp7/ethics_en.html





Timeline: Dall'idea al progetto





EUROPEAN
COMMISSION

Community research

Dossier APRE: analisi della partecipazione italiana

A P R E
A G E N Z I A
P E R L A
P R O M O Z I O N E
D E L L A
R I C E R C A
E U R O P E A

Analysis of research proposals submitted
by Italian coordinators to the thematic
priority "Life sciences, genomics and biotechnology for Health"
of the 6th EU Framework Programme for Research
and Technological Development
(2002 - 2006)

*Making Italian researchers more
successful in the proposal writing*

Dossier APRE n. 11

P. ZZA GUGLIELMO
MARCONI 25, 00144 ROMA
TEL. ++39 065911817
FAX ++39 065911908
EMAIL: SEGRETERIA@APRE.IT
SITO INTERNET :
WWW.APRE.IT





- *Verificare che il progetto sia pienamente rispondente al topic e che conosciate lo stato dell'arte a livello europeo/mondiale.*
- *Inviateci la proposta quando è a un buono stato di draft per una prima lettura*
- *Curate tutti gli aspetti collaterali alla ricerca (impatto socio-economico, aspetti etici, impiego delle risorse)*



EUROPEAN
COMMISSION

Community research



www.smesgohealth.org



www.spidera.eu



www.efbicred.com





The Health Directorate

Director (acting) – Dr. Manuel Hallen:

Medical and Public Health Research unit (F2)

Head of unit: Dr. Manuel Hallen (manuel.hallen@ec.europa.eu)

Deputy Head of Unit: Dr. Maria Vidal (maria-jose.vidal-ragout@ec.europa.eu)

Head of sector Public Health: K. McCarthy (kevin.mccarthy@ec.europa.eu)

Infectious Diseases unit (F3)

Head of unit: Dr. Alain Vanvossel (alain.vanvossel@ec.europa.eu)

Deputy Head of unit: Dr. Anna Lönnroth (anna.lonnroth@ec.europa.eu)

Head of IMI sector: Dr. Irene Norstedt (irene.norstedt@ec.europa.eu)

Genomics and Systems Biology unit (F4)

Head of unit: Patrik Kolar (patrik.kolar@ec.europa.eu)

Deputy Head of unit: Dr. B. Mulligan (bernard.mulligan@ec.europa.eu)

Health Biotechnology unit (F5)

Head of unit: Dr. Arnd Hoeveler (arnd.hoeveler@ec.europa.eu)

Coordination unit (F1)

Head of unit: Stéphane Hogan
(stephane.hogan@ec.europa.eu)

Admin. & Finance unit (F6)

Head of unit: Giorgios Zisimatos
(giorgios.zisimatos@ec.europa.eu)





EUROPEAN
COMMISSION

Community research

Contacts & Information

FP7 Health web site: <http://cordis.europa.eu/fp7/health>

NCPs: http://cordis.europa.eu/fp7/health/support_en.html

Registration as an **Expert:** <https://cordis.europa.eu/emmfp7/>

SMEsgoHealth: www.smesgohealth.org

FP6 projects database: www.lifecompetence.eu

SME participation: Dr. Ludovica Serafini

Tel. +32 2 295 6759 – Email: ludovica.serafini@ec.europa.eu

International Cooperation: Dr. Indridi Benediktsson

Tel. +32 2 299 3137 – Email: indridi.benediktsson@ec.europa.eu





EUROPEAN
COMMISSION

Community research

Contacts & Information

buonocore@apre.it

06 5911817

Grazie dell'attenzione !